CUTAQUIG (Immune Globulin Subcutaneous [Human] - hipp) is a 16.5% immune globulin solution for subcutaneous infusion (IGSC), indicated as replacement therapy for primary humoral immunodeficiency (PI) in adults and pediatric patients 2 years of age and older. This includes, but is not limited to, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia , See risks & benefits. Learn about CUTAQUIG® as an Rx option for adults & pediatric patients aged 2 years and older with primary immunodeficiency (PI) disease., To this end, the efficacy and safety of SCIG 16.5% (Cutaquig®, Octapharma AG), at enhanced infusion regimens, was evaluated. SCIG 16.5% is currently approved for the treatment of PIDD in the US and Europe and for secondary immunodeficiencies in Europe and Canada [22 – 24]., This step-by-step guide will help you to administer cutaquig®subcutaneously. Cutaquig®contains immunoglobulin G (IgG), helping your immune system to fight off bacterial and viral infections. Cutaquig®is a medicine for people who are born with a reduced ability or inability to produce antibodies (primary immunodeficiency), or who are suffering from an acquired deficiency of antibodies , What Makes cutaquig Different? Cutaquig is a 16.5% immunoglobulin solution for subcutaneous infusion indicated for the treatment of PI in adult patients. The most significant difference between cutaquig and other SCIg products is its 16.5% concentration., CUTAQUIG (Immune Globulin Subcutaneous (Human) - hipp) is a 16.5% immune globulin solution for subcutaneous infusion indicated for treatment of primary humoral immunodeficiency (PI) in adults and .